Pharmacology is the scientific study of drugs and their interactions with living systems. it is broadly divided into two main branches:
pharmacokinetics and
pharmacodynamics.
Pharmacokinetics Pharmacokinetics refers to the movement of drugs within the body and describes what the body does to a drug. It includes five main processes: •
Liberation – When the
active pharmaceutical ingredient is released from its
pharmaceutical formulation and becomes available for absorption. •
Absorption – How the drug enters the bloodstream. •
Distribution – How the drug spreads throughout the body's tissue and fluids. •
Metabolism – How the drug is chemically altered, primarily in the liver. •
Excretion – How the drug and its metabolites are eliminated, mainly through the kidneys.
Key physiological parameters in pharmacokinetics include • '
Half-life (t
½) –' The time required for the drug's plasma concentration to reduce by half. • '
Volume of distribution (VD
) –' A theoretical volume that relates the total amount of a drug in the body to its measured concentration in the blood (or plasma). • '
Total Clearance (Cl
tot) –' A theoretical pharmacokinetic parameter that statistically explains the efficiency with which a drug is irreversibly eliminated from the body, quantified as the volume of plasma cleared of the drug per unit of time, typically measured in L/h or mL/min. •
Area Under the Curve (AUC) – The definite integral of the plasma drug concentration versus time curve from time zero to infinity, which represents the total systemic exposure of the body to a drug overtime (AUC0−∞).
Pharmacodynamics Pharmacodynamics refers to the biochemical and physiological effects of drugs on the body and the mechanism of the action. it answers the question, "What does the drug do to the body?" This include : •
Receptor binding – Most drugs exert their effects by binding to specific cell receptors (proteins on cell surfaces or inside cells) •
Dose-response relationship – Illustrated using drug-response curves, these relationships show the effect of different drug doses on the magnitude of a response. •
Therapeutic window – The range of doses between the minimum effective concentration and the minimum toxic concentration. s. Dose response curves are studied extensively in pharmacology.
Systems, receptors and ligands synapse. Targets in synapses can be modulated with pharmacological agents. In this case,
cholinergics (such as
muscarine) and
anticholinergics (such as
atropine) target receptors;
transporter inhibitors (such as
hemicholinium) target membrane transport proteins and
anticholinesterases (such as
sarin) target enzymes. Pharmacology is often studied by focusing on specific systems, such as endogenous neurotransmitter systems. The major systems studied in pharmacology can be categorized by their
ligands and their
receptors which include, but are not limited to,
acetylcholine (ACh),
adenosine,
adrenaline,
anandamide,
aspartate,
glutamate,
glycine,
purines,
substance P,
eicosanoids,
GABA,
dopamine (DA),
histamine,
serotonin (5-HT),
serine,
cannabinoids,
opioids,
melatonin,
vasopressin (ADH), and
norepinephrine (NE). Molecular targets in pharmacology include receptors,
enzymes, and
membrane transport proteins. Enzymes can be targeted with
enzyme inhibitors. Receptors are typically categorized based on structure and function. Major receptor types studied in pharmacology include
G protein coupled receptors,
ligand gated ion channels, and
receptor tyrosine kinases. Network pharmacology is a subfield of pharmacology that combines principles from pharmacology,
systems biology, and network analysis to study the complex interactions between drugs and targets (receptors or enzymes etc.) in biological systems. The topology of a biochemical reaction network determines the shape of drug
dose-response curve as well as the type of drug-drug interactions, thus can help designing efficient and safe therapeutic strategies. The topology Network pharmacology utilizes computational tools and network analysis algorithms to identify drug targets, predict drug-drug interactions, elucidate signaling pathways, and explore the
polypharmacology of drugs.
Pharmacodynamics Pharmacodynamics is defined as how the body reacts to the drugs. Pharmacodynamics theory often investigates the
binding affinity of
ligands to their receptors. Ligands can be
agonists, partial agonists or
antagonists at specific receptors in the body. Agonists bind to receptors and produce a biological response, a partial agonist produces a biological response lower than that of a full agonist, antagonists have affinity for a receptor but do not produce a biological response. The ability of a ligand to produce a biological response is termed
efficacy, in a dose-response profile it is indicated as percentage on the y-axis, where 100% is the maximal efficacy (all receptors are occupied). Binding affinity is the ability of a ligand to form a ligand-receptor complex either through
weak attractive forces (reversible) or
covalent bond (irreversible), therefore efficacy is dependent on binding affinity.
Potency of drug is the measure of its effectiveness,
EC50 is the drug concentration of a drug that produces an efficacy of 50% and the lower the concentration the higher the potency of the drug therefore EC50 can be used to compare potencies of drugs. Medication is said to have a narrow or wide
therapeutic index, certain safety factor, or
therapeutic window. This describes the ratio of desired effect to toxic effect. A compound with a narrow therapeutic index (close to one) exerts its desired effect at a dose close to its toxic dose. A compound with a wide therapeutic index (greater than five) exerts its desired effect at a dose substantially below its toxic dose. Those with a narrow margin are more difficult to dose and administer, and may require
therapeutic drug monitoring (examples are
warfarin, some
antiepileptics,
aminoglycoside antibiotics). Most anti-
cancer drugs have a narrow therapeutic margin: toxic side-effects are almost always encountered at doses used to kill
tumors. The effect of drugs can be described with
Loewe additivity which is one of several common reference models. When describing the pharmacokinetic properties of the chemical that is the active ingredient or
active pharmaceutical ingredient, pharmacologists are often interested in
L-ADME: •
Liberation – How is the active pharmaceutical ingredient disintegrated (for solid oral forms (breaking down into smaller particles), dispersed, or dissolved from the medication? •
Absorption – How is the active pharmaceutical ingredient absorbed (through the
skin, the
intestine, the
oral mucosa)? •
Distribution – How does the active pharmaceutical ingredient spread through the organism? •
Metabolism – Is the active pharmaceutical ingredient converted chemically inside the body, and into which substances. Are these active (as well)? Could they be toxic? •
Excretion – How is the active pharmaceutical ingredient excreted (through the bile, urine, breath, skin)?
Drug metabolism is assessed in pharmacokinetics and is important in drug research and prescribing. Pharmacokinetics is the movement of the drug in the body, it is usually described as 'what the body does to the drug' the physico-chemical properties of a drug will affect the rate and extent of absorption, extent of distribution, metabolism and elimination. The drug needs to have the appropriate molecular weight, polarity etc. in order to be absorbed, the fraction of a drug that reaches the systemic circulation is termed bioavailability, this is simply a ratio of the peak plasma drug levels after oral administration and the drug concentration after an IV administration (first pass effect is avoided and therefore no amount drug is lost). A drug must be lipophilic (lipid soluble) in order to pass through biological membranes because biological membranes are made up of a lipid bilayer (phospholipids etc.). Once the drug reaches the blood circulation it is then distributed throughout the body and being more concentrated in highly perfused organs.
Gene expression modulation and epigenetics Apart from classical pharmacological targets, drugs may exert effects through direct or indirect gene expression
modulation, or even introduce persistent state changes through epigenetic
reprogramming. Therefore, drugs should be screened for
off-target activity by
gene expression profiling, in addition to conventional ligand binding, enzyme assays, etc. == Administration, drug policy and safety ==